Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Employment agrmnt
Quarterly results
NOVADEL PHARMA INC (NVDL) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/16/2011 8-K Quarterly results
Docs: "NovaDel Reports Financial Results for First Quarter 2011"
08/16/2010 8-K Form 8-K - Current report
05/17/2010 8-K Form 8-K - Current report
11/17/2009 8-K Quarterly results
Docs: "NovaDel Reports Financial Results for Third Quarter and Nine Months ended September 30, 2009"
08/12/2009 8-K Quarterly results
Docs: "NovaDel Reports Financial Results for Second Quarter and Six Months ended June 30, 2009"
05/15/2009 8-K Form 8-K -- Current report
11/12/2008 8-K Quarterly results
Docs: "NovaDel Reports Financial Results for Third Quarter 2008"
08/07/2008 8-K Quarterly results
Docs: "NovaDel Reports Financial Results for Second Quarter 2008"
05/16/2008 8-K Quarterly results
Docs: "NovaDel Reports Financial Results for First Quarter 2008 -NovaDel Receives Notification of Possible Delisting from AMEX for Non-Compliance with Certain Listing Standards-"
11/15/2007 8-K Quarterly results
Docs: "NovaDel Reports Financial Results for Third Quarter 2007"
08/21/2007 8-K Quarterly results
Docs: "NovaDel Reports Financial Results for Second Quarter 2007 Flemington, NJ -August 14, 2007-NovaDel Pharma Inc. , a specialty pharmaceutical company developing oral spray formulations for a broad range of marketed treatments, reported financial results for its second quarter ended June 30, 2007. For the quarter ended June 30, 2007, NovaDel reported a net loss of $5.3 million, or $0.09 cents per share, compared to a net loss of $5.4 million, or $0.09 cents per share, for the previous quarter ended March 31, 2007. The net loss was primarily attributable to continuing research and development expenses, and general and administrative expenses during the second quarter ended June 30, 2007. To date, the Company's total operating expenses have been primarily focused on the clinical and developmenta..."
05/16/2007 8-K Quarterly results
Docs: "NovaDel Reports Financial Results for First Quarter 2007 Flemington, NJ - May 15, 2007 - NovaDel Pharma Inc. , a specialty pharmaceutical company developing oral spray formulations for a broad range of marketed treatments, reported results for its first quarter ended March 31, 2007. For the quarter ended March 31, 2007, NovaDel reported a net loss of $5.4 million, or $0.09 cents per share, compared to a net loss of $2.1 million, or $0.05 cents per share, for the quarter ended April 30, 2006. NovaDel recently changed its fiscal year end from July 31 to December 31, effective December 31, 2006. The increase in net loss was primarily attributable to a decrease in revenue associated with a $1.0 million non-recurring milestone payment received in the quarter ended April 30, 2006, as well as inc..."
12/21/2006 8-K Quarterly results
Docs: "NovaDel Reports First Quarter Results",
"NovaDel Issued Second Canadian Patent for Oral Spray Delivery of Major Classes of Pharmaceuticals"
11/01/2006 8-K Quarterly results
Docs: "NovaDel Reports Fourth Quarter and Full Year Fiscal 2006 Financial Results Recent Highlights Include Positive Data on Sumatriptan Oral Spray",
"NovaDel Announces Positive Results from Pilot Study of Zolpidem Oral Spray vs. Ambien Tablets -Company Plans to Launch Pivotal Trial in First Quarter 2007-"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy